Cognition Therapeutics Inc Overview
Pro stress-test →Cognition Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative and neurocognitive disorders, headquartered in Pittsburgh, Pennsylvania and founded in 2007. The company focuses on addressing unmet medical needs in diseases such as Alzheimer's disease, Parkinson's disease, and other central nervous system disorders.
Strategic Profile
Pro stress-test →The company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer's disease. Following strong phase II results, the company is prioritizing zervimesine for DLB psychosis with registrational trial planning underway, and its cash runway extends through Q2 2027, with START trial results expected in 2027.
Competitive Landscape
Pro stress-test →Cognition Therapeutics develops small-molecule therapeutics aimed at treating age-related degenerative diseases and disorders of the central nervous system. The company competes in the neurodegenerative disease space where larger pharmaceutical companies and emerging biotechs are developing disease-modifying treatments for Alzheimer's, Parkinson's, and Lewy body diseases.
Industry Context
Cognition Therapeutics Inc operates in Biopharmaceuticals/Neurodegenerative Therapeutics.
Key facts
Founded: 2007 · Headquarters: Pittsburgh, US · Employees: 25 · Revenue: N/A · Market cap: $95.34M